Conjugate Vaccines
Conjugate vaccines convert T-cell–independent capsular polysaccharide antigens into T-cell–dependent immunogens by covalent linkage to carrier proteins. This enhances immunologic memory, affinity maturation, and efficacy in infants and immunocompromised adults, reducing invasive disease from encapsulated pathogens such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae.
Technical Challenges
Heterogeneity of polysaccharide antigens complicates consistent conjugation and potency.
Thermostability and cold-chain dependence limit deployment in austere and prolonged-field-care environments.
Reduced immunogenicity in immunocompromised or heavily pre-exposed populations and elderly service members.
Manufacturing scale-up and batch-to-batch consistency for novel glycoconjugates remains resource-intensive.
Emerging Opportunities
Rapidly deployable, thermostable conjugate formulations suitable for austere settings and prolonged field care.
Platform technologies enabling fast design and clinical translation against emerging bacterial threats.
Improved carriers and adjuvant strategies to boost responses in immunosenescent and immunocompromised personnel.
Manufacturing approaches that reduce cost, increase throughput, and ensure consistent glycan presentation.
Current and Emerging Technologies in Conjugate Vaccines
Polysaccharide–Protein Conjugation Chemistry
Click chemistry, reductive amination, and linker chemistries improve site-specific conjugation to control glycan:protein ratios and presentation, enhancing reproducible immunogenicity.
Synthetic Oligosaccharide and Glycoengineering
Chemical synthesis and enzymatic glycoengineering produce defined oligosaccharides for precise vaccine antigens, reducing variability inherent in native polysaccharide extraction.
Carrier Protein Optimization & Novel Carriers
Alternatives to CRM197 and toxoid carriers, including recombinant proteins and nanoparticle scaffolds, aim to reduce carrier-induced immune interference and broaden T-cell help.
Nanoparticles, VLPs, and Multivalent Display
Virus-like particles and synthetic nanoparticle platforms present multiple glycan epitopes to mimic pathogen architecture, improving B-cell activation and enabling dose sparing.
Formulation, Adjuvants, and Thermostable Delivery
Lyophilized, single-dose, and adjuvanted formulations—including novel TLR and saponin-based adjuvants—support durable immunity and reduce cold-chain dependence for forward-deployed forces.
Importance to Military Medicine
Force Readiness and Outbreak Prevention
Prevention of invasive bacterial disease preserves operational capability and reduces mission-impacting morbidity during deployments and training.
Austere and Prolonged Field Care
Thermostable conjugates and single-dose strategies enable immunization where cold chain and evacuation are limited, protecting personnel in forward and prolonged-care settings.
Reduced Evacuation and Clinical Burden
Preventing vaccine-preventable bacterial sepsis and meningitis decreases medevac requirements and conserves scarce surgical and critical care resources.
Biodefense and Contingency Preparedness
Conjugate platforms can be leveraged for rapid response to bacterial threats and for improving prophylaxis in mass-casualty or outbreak scenarios.
Alignment with the MTEC Mission
Directly supports DoD readiness priorities by preventing infectious disease that undermines unit effectiveness.
Enables rapid translation of improved vaccine platforms—aligning with MTEC’s mission to accelerate medical technologies for Warfighters.
Addresses biodefense and outbreak resilience, a core MTEC portfolio area in infectious disease and force health protection.
Supports dual-use impact—civilian public health benefits accelerate acceptance and scale for military-relevant vaccines.
Dual-Use (Military + Civilian) Applications
Pre-deployment immunization programs to reduce mission-limiting bacterial disease.
Austere-point vaccination with thermostable conjugates during prolonged-field-care or expeditionary operations.
Rapid-response platform vaccines for emergent encapsulated-bacteria threats and biodefense scenarios.
Explore MTEC Members with Conjugate Vaccines Capabilities
MTEC members bring multidisciplinary strengths—glycochemistry, clinical vaccinology, biomanufacturing, and forward-deployment logistics—to advance conjugate vaccine candidates. Explore member profiles to identify partners for platform development, thermostable formulation, clinical trials under DoD constraints, and rapid scale-up for both military and civilian use.
92 Members with Conjugate Vaccines capabilities.
The University of Texas System is a leading public university system in the United States, dedicated to improving lives through education, health care, and research. With over 256,000 students enrolled across 14 institutions, the UT System is committed to providing affordable access to higher education and producing a skilled workforce to drive Texas's economy.
Georgia Southern University is a vibrant institution with over 26,100 students across three campuses in Statesboro, Savannah, and Hinesville. The university offers 132 degree programs at the associate, bachelor’s, master’s, and doctorate levels, emphasizing student success, community impact, and research excellence. With a commitment to inclusivity and engagement, Georgia Southern fosters a supportive environment for diverse learners, including military-affiliated and adult students. The university is dedicated to transforming lives through education and community engagement, aligning its programs with regional needs. Additionally, Georgia Southern provides accelerated pathways for students to fast-track their master's degrees, enhancing educational opportunities. The university also emphasizes career readiness and public impact research, preparing students for successful careers and contributing to community development.
STAT Therapeutics is focused on developing a drug- device combination for easy, rapid administration of intramuscular, life-saving medications by users in any setting, aiming to improve access and usability for acute emergency treatments such as pain, anaphylaxis, and seizures.
The University of Texas at San Antonio (UTSA) is dedicated to the advancement of knowledge through research, teaching, and community engagement. As a premier public research university, UTSA embraces multicultural traditions and serves as a catalyst for socioeconomic development, providing access to educational excellence and preparing citizen leaders for the global environment.
Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.
BioPharma Connections is an independent, woman-owned consulting firm founded in San Francisco in 2007, providing strategic business development, technical operations, regulatory, product development, and commercialization support to the life sciences industry. Serving pharmaceutical, biotechnology, medical device, and diagnostic companies globally, the firm specializes in facilitating connections between organizations, service providers, CROs, CDMOs, and investors—guiding clients from concept to commercialization, with deep expertise in regulatory compliance, emerging technologies, and diverse therapeutic areas.
The Institute for Integrative & Innovative Research (I³R) at the University of Arkansas is dedicated to pioneering solutions to wicked problems and societal challenges through convergence research. With a mission to advance research excellence and stimulate economic development, I³R focuses on deploying innovations at scale through collaboration across various sectors, including academia, industry, and government.
UTMB is dedicated to supporting research, education, and scholarly endeavors, with a focus on creating the future of healthcare through innovative research and community engagement.
Revolution Biomanufacturing Inc. (RBIx) is expanding beyond traditional CDMO Process/Analytical Development and Manufacturing services to pioneer distributed molecular manufacturing. A new class of digital biomanufacturing that enables the autonomous design, manufacture, quality verification, and deployment of Nucleic Acid therapeutics and molecular diagnostics at the point of need. By integrating AI-driven sequence optimization, enzymatic nucleic acid synthesis, Nanoparticle design and manufacturing (LNP & EV), closed-loop quality control, and field-deployable manufacturing platforms, RBIx is creating adaptive biological infrastructure capable of responding to emerging diseases, national security threats, and personalized medicine with unprecedented speed and flexibility.
The University of Chicago is a prestigious urban research university committed to rigorous inquiry and intellectual freedom. Founded in 1890, it has produced numerous Nobel laureates and is known for its transformative education and groundbreaking research across various fields. The university fosters an inclusive and diverse learning environment, encouraging participation from all community members.
Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.
Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.
Base Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.
The Nanovaccine Institute, established at Iowa State University in 2017, is a national transdisciplinary research consortium focused on advancing nano-based technologies to treat and prevent diseases. The institute aims to revolutionize public health outcomes through the design and promotion of nano-based vaccines and therapeutics.
The UT Arlington Research Institute (UTARI) specializes in applying cutting-edge technologies to real-world engineering problems. Our collaborative endeavors reflect a commitment to excellence, integrity, and respect for all, bringing economic growth and fulfillment to our families, business partners, university, and community.
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue. The company aims to restore people's bodies and their self-belief by using technology to take the limits off living. With a commitment to medical education and improving patient outcomes, Smith+Nephew operates in over 100 countries and is dedicated to sustainability and community health. Their purpose is to promote health and wellbeing, not just through their products but also by ensuring a positive impact on society and the environment. Smith+Nephew is also committed to increasing diversity within the medical device industry through initiatives like the Orthopaedics for All global advisory board.

Safi Biotherapeutics
Next-Generation Manufactured Red Blood Cells for Extended Battlefield Blood Supply: Safi Biotherapeutics
Safi Biotherapeutics is developing manufactured red blood cells (mRBCs) with extended shelf life to improve battlefield transfusion readiness and emergency trauma care.
Non-Invasive Glymphatic (GF) Monitoring and Recovery Optimization for Warfighter Cognitive Readiness
Applied Cognition is developing non-invasive glymphatic monitoring and recovery technologies to enhance warfighter cognitive readiness, resilience, and sleep recovery.
Moberg Analytics
Moberg Analytics – Advanced Brain Monitoring & Critical Care Informatic
Moberg’s platform unifies brain monitoring data for faster, precise treatment of severe brain injuries in military and civilian care.
University of California San Francisco
TemPredict: AI-Driven Wearable Monitoring for Early Illness Detection and Warfighter Readiness
TemPredict: AI wearables detect early illness and health risks to support warfighter readiness.